Literature DB >> 31433346

Long-Acting Injectable Aripiprazole for a Schizophrenic Patient Concomitant With Stimulant Use Disorder.

Shih-Fen Chen1, Yu-Chih Shen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31433346     DOI： 10.1097/JCP.0000000000001087

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  2 in total

1.  Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study.

Authors:  Pierre-Michel Llorca; Philippe Nuss; Éric Fakra; Isabelle Alamome; Dominique Drapier; Wissam El Hage; Renaud Jardri; Stéphane Mouchabac; Marc Rabbani; Nicolas Simon; Marie-Noëlle Vacheron; Jean-Michel Azorin
Journal:  BMC Psychiatry       Date:  2022-05-28       Impact factor: 4.144

2.  Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review.

Authors:  Alexandria S Coles; Dunja Knezevic; Tony P George; Christoph U Correll; John M Kane; David Castle
Journal:  Front Psychiatry       Date:  2021-12-15       Impact factor: 4.157
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.